Exchange: NASDAQ·Updated 07:48 AM EDT
SPRO logo

SPRO Spero Therapeutics Inc

$1.25
$0.02
(1.63%)
Pre-Market
Prev Close $1.23
Reported EarningsAug 12
Mkt Cap$71.63M
Vol943.00

About SPRO

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.
30

Bearish Sentiment

How do you feel about SPRO?

Advertisement|Remove ads.